JP7584218B2 - Ｉｌ－４ｒアンタゴニストを投与することによりアレルギーを予防又は処置するための方法 - Google Patents

Ｉｌ－４ｒアンタゴニストを投与することによりアレルギーを予防又は処置するための方法 Download PDF

Info

Publication number
JP7584218B2
JP7584218B2 JP2019511889A JP2019511889A JP7584218B2 JP 7584218 B2 JP7584218 B2 JP 7584218B2 JP 2019511889 A JP2019511889 A JP 2019511889A JP 2019511889 A JP2019511889 A JP 2019511889A JP 7584218 B2 JP7584218 B2 JP 7584218B2
Authority
JP
Japan
Prior art keywords
antagonist
dose
administered
pharmaceutical composition
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019511889A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019531273A (ja
JP2019531273A5 (enExample
Inventor
ジェニファー・ディー・ハミルトン
ブライアン・エヌ・スワンソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59923551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7584218(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2019531273A publication Critical patent/JP2019531273A/ja
Publication of JP2019531273A5 publication Critical patent/JP2019531273A5/ja
Priority to JP2022134609A priority Critical patent/JP7542582B2/ja
Priority to JP2024137494A priority patent/JP2024164098A/ja
Application granted granted Critical
Publication of JP7584218B2 publication Critical patent/JP7584218B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
JP2019511889A 2016-09-01 2017-08-31 Ｉｌ－４ｒアンタゴニストを投与することによりアレルギーを予防又は処置するための方法 Active JP7584218B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022134609A JP7542582B2 (ja) 2016-09-01 2022-08-26 Ｉｌ－４ｒアンタゴニストを投与することによりアレルギーを予防又は処置するための方法
JP2024137494A JP2024164098A (ja) 2016-09-01 2024-08-19 Ｉｌ－４ｒアンタゴニストを投与することによりアレルギーを予防又は処置するための方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662382501P 2016-09-01 2016-09-01
US62/382,501 2016-09-01
US201662425726P 2016-11-23 2016-11-23
US62/425,726 2016-11-23
PCT/US2017/049538 WO2018045130A1 (en) 2016-09-01 2017-08-31 Methods for preventing or treating allergy by administering an il-4r antagonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022134609A Division JP7542582B2 (ja) 2016-09-01 2022-08-26 Ｉｌ－４ｒアンタゴニストを投与することによりアレルギーを予防又は処置するための方法

Publications (3)

Publication Number Publication Date
JP2019531273A JP2019531273A (ja) 2019-10-31
JP2019531273A5 JP2019531273A5 (enExample) 2020-10-01
JP7584218B2 true JP7584218B2 (ja) 2024-11-15

Family

ID=59923551

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019511889A Active JP7584218B2 (ja) 2016-09-01 2017-08-31 Ｉｌ－４ｒアンタゴニストを投与することによりアレルギーを予防又は処置するための方法
JP2022134609A Active JP7542582B2 (ja) 2016-09-01 2022-08-26 Ｉｌ－４ｒアンタゴニストを投与することによりアレルギーを予防又は処置するための方法
JP2024137494A Pending JP2024164098A (ja) 2016-09-01 2024-08-19 Ｉｌ－４ｒアンタゴニストを投与することによりアレルギーを予防又は処置するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022134609A Active JP7542582B2 (ja) 2016-09-01 2022-08-26 Ｉｌ－４ｒアンタゴニストを投与することによりアレルギーを予防又は処置するための方法
JP2024137494A Pending JP2024164098A (ja) 2016-09-01 2024-08-19 Ｉｌ－４ｒアンタゴニストを投与することによりアレルギーを予防又は処置するための方法

Country Status (14)

Country Link
US (2) US11771743B2 (enExample)
EP (2) EP3506931B1 (enExample)
JP (3) JP7584218B2 (enExample)
KR (3) KR20240065318A (enExample)
CN (2) CN109789196B (enExample)
CA (1) CA3035202A1 (enExample)
ES (1) ES2994774T3 (enExample)
HU (1) HUE067888T2 (enExample)
IL (2) IL265104B2 (enExample)
MA (1) MA46098B1 (enExample)
MX (2) MX2019002344A (enExample)
PL (1) PL3506931T3 (enExample)
PT (1) PT3506931T (enExample)
WO (1) WO2018045130A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
TWI656880B (zh) 2012-08-21 2019-04-21 法商賽諾菲生物技術公司 投與ｉｌ－４ｒ拮抗劑以治療或預防氣喘之方法
HUE039387T2 (hu) 2012-09-07 2018-12-28 Regeneron Pharma Atópiás dermatitisz kezelési módszerei egy IL-4R antagonista adagolásával
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
AU2015222951B2 (en) 2014-02-28 2020-06-11 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an IL-4R antagonist
WO2016077675A1 (en) 2014-11-14 2016-05-19 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
CN107474134B (zh) 2016-06-08 2021-07-27 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
CN109789196B (zh) 2016-09-01 2024-03-19 瑞泽恩制药公司 用于通过施用il-4r拮抗剂来预防或治疗变态反应的方法
WO2019028367A1 (en) * 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
PT3515465T (pt) 2017-08-18 2024-03-04 Regeneron Pharma Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
ES2969049T3 (es) 2017-10-30 2024-05-16 Sanofi Biotechnology Antagonista de IL-4R para uso en un método para tratar o prevenir el asma
SG11202009371WA (en) 2018-05-13 2020-10-29 Regeneron Pharma Methods for treating atopic dermatitis by administering an il-4r inhibitor
JP7335333B2 (ja) * 2018-11-07 2023-08-29 シーサン・セラピューティクス 皮膚透過性核酸複合体を有効成分として含有するアトピー皮膚炎の予防又は治療用組成物
US11312778B2 (en) 2018-11-21 2022-04-26 Brian C. Machler Method for treating allergic contact dermatitis
CN110746507B (zh) 2018-12-25 2020-06-26 江苏荃信生物医药有限公司 抗人白介素4受体α单克隆抗体及其应用
CN121102493A (zh) * 2019-03-21 2025-12-12 瑞泽恩制药公司 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合
CN115175700A (zh) 2019-07-16 2022-10-11 赛诺菲生物技术公司 用于通过施用il-4r拮抗剂治疗或预防哮喘的方法
SG11202113312VA (en) 2019-08-05 2021-12-30 Regeneron Pharma Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
EP4010373A1 (en) 2019-08-05 2022-06-15 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
MX2022006992A (es) 2019-12-09 2022-07-13 Sanofi Biotechnology Metodos para tratar los trastornos relacionados con il-4/il-13 identificados digitalmente.
EP3992974A1 (en) 2020-11-02 2022-05-04 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
EP4081544A1 (en) * 2019-12-23 2022-11-02 Sanofi Biotechnology Methods for treating or preventing allergic asthma by administering an il-33 antagonist and/or an il-4r antagonist
MX2023007945A (es) * 2021-01-08 2023-09-21 Regeneron Pharma Metodos para tratar la alergia al cacahuate y mejorar la inmunoterapia especifica de alergeno del cacahuate mediante la administracion de un antagonista de il-4r.
CN114805572B (zh) * 2021-01-22 2022-12-13 上海济煜医药科技有限公司 抗原结合蛋白及其应用
KR20230111729A (ko) 2022-01-19 2023-07-26 연세대학교 원주산학협력단 단삼 추출물을 유효성분으로 포함하는 알레르기 질환 예방 또는 치료용 조성물
KR20250007616A (ko) * 2022-04-29 2025-01-14 아케소 바이오파마, 인크. 항-인간 il-4ra 항체 및 이의 용도
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods
WO2025245354A1 (en) * 2024-05-22 2025-11-27 Halozyme, Inc. Combination therapy with dupilumab and hyaluronidases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015527364A (ja) 2012-08-21 2015-09-17 サノフイ Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8808015D0 (en) 1988-04-06 1988-05-05 Ritter M A Chemical compounds
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
EP0668774A1 (en) 1991-05-03 1995-08-30 Seragen, Inc. Interleukin receptor targeted molecules for treatment of inflammatory arthritis
JP3315427B2 (ja) 1992-03-05 2002-08-19 大日本除蟲菊株式会社 皮膚炎治療剤
US5714146A (en) 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
ZA946875B (en) 1993-09-07 1995-07-06 Smithkline Beecham Corp Recombinant il4 antibodies useful in treatment of il4 mediated disorders
ES2259478T3 (es) 1998-09-18 2006-10-01 Dynavax Technologies Corporation Metodos para tratar trastornos asociados con la ige y composiciones para este uso.
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
WO2001092340A2 (en) 2000-05-26 2001-12-06 Immunex Corporation Use of interleukin-4 antagonists and compositions thereof
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
EP1304115B1 (en) 2000-07-26 2007-09-12 Hououdou Co. Ltd. Antipruritic compositions and compositions promoting wound healing
PT1345624E (pt) 2000-12-22 2006-09-29 Nestle Sa Inducao de tolerancia
US20030103938A1 (en) 2001-05-09 2003-06-05 Alk-Abello A/S Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio
US20050031609A1 (en) 2001-05-11 2005-02-10 Thomas Hultsch Compositions for use in treating ige-associated disorders
US20050074462A1 (en) 2001-05-23 2005-04-07 Duotol Ab Supression of allergic reactions by transdermal administration of allergens conjugated to cholera toxin or fragments thereof
AR037456A1 (es) 2001-11-30 2004-11-10 Biogen Inc Anticuerpos contra proteinas quimiotacticas monocitarias
CA2479927C (en) 2002-03-29 2013-03-12 Schering Corporation Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
MXPA05005528A (es) 2002-11-26 2006-04-05 Alk Abello As Producto farmaceutico de alergeno.
PT2000481E (pt) 2003-02-01 2016-06-17 Tanox Inc Anticorpos anti-ige humana de alta afinidade
US7923209B2 (en) 2003-03-14 2011-04-12 Anergis, S.A. Allergen peptide fragments and use thereof
CA2543982C (en) 2003-11-07 2013-01-08 Immunex Corporation Antibodies that bind interleukin-4 receptor
AU2004309373A1 (en) 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
DE602005006758D1 (de) 2004-02-27 2008-06-26 Regeneron Pharma Il-4/il-13-spezifische polypetide und deren therapeutische verwendung
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
JP5234445B2 (ja) 2004-10-05 2013-07-10 源一郎 杣 薬剤
US8030003B2 (en) 2004-12-07 2011-10-04 Children's Hospital Medical Center Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
TWI306862B (en) 2005-01-03 2009-03-01 Hoffmann La Roche Antibodies against il-13 receptor alpha 1 and uses thereof
AU2006244180B2 (en) 2005-05-06 2012-03-01 Zymogenetics, Inc. IL-31 monoclonal antibodies and methods of use
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
JP4221018B2 (ja) 2006-08-31 2009-02-12 トヨタ自動車株式会社 頭部保護エアバッグ装置
CA2664343C (en) 2006-10-02 2016-04-26 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
UA102994C2 (ru) 2007-03-22 2013-09-10 Дженентек, Инк. АНТИТЕЛО, КОТОРОЕ СПЕЦИФИЧНО СВЯЗЫВАЕТСЯ С IgE/M1' И ИНДУЦИРУЕТ АПОПТОЗ В ЭКСПРЕССИРУЮЩИХ IgE В-КЛЕТКАХ
EP2022507A1 (en) 2007-08-07 2009-02-11 Universität Hamburg Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy
WO2009061819A1 (en) 2007-11-05 2009-05-14 The Regents Of The University Of Colorado Minimally-invasive measurement of esophageal inflammation
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
DE202008006598U1 (de) 2008-04-11 2008-10-02 Alk-Abelló A/S Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung
US20090264392A1 (en) 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
WO2010065557A2 (en) 2008-12-01 2010-06-10 Cincinnati Children's Hospital Medical Center Methods of determining efficacy of glucocorticoid treatment of eosinophilic esophagitis
WO2010120511A2 (en) 2009-03-31 2010-10-21 Altair Therapeutics, Inc. Method of treating respiratory disorders
US8497528B2 (en) 2010-05-06 2013-07-30 Taiwan Semiconductor Manufacturing Company, Ltd. Method for fabricating a strained structure
CA2773234C (en) 2009-09-07 2017-11-28 Dbv Technologies Method of treating eosinophilic esophagitis
US8993347B2 (en) 2009-12-17 2015-03-31 Cornell University Methods for detecting antibodies in mucosal samples and device for sampling mucosal material
EP3970726A1 (en) 2010-06-24 2022-03-23 ViroPharma Biologics LLC Methods of treatment for esophageal inflammation
SG189220A1 (en) 2010-10-06 2013-05-31 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
HRP20180421T1 (hr) 2010-11-17 2018-04-20 Chugai Seiyaku Kabushiki Kaisha Višestruko specifične molekule za vezanje na antigen koje imaju alternativnu funkciju u odnosu na funkciju faktora viii zgrušavanja krvi
RU2453303C1 (ru) 2010-12-23 2012-06-20 Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") Фармацевтическая композиция для лечения атопического дерматита
WO2012094643A2 (en) 2011-01-06 2012-07-12 Children's Hospital Medical Center Esophageal cytokine expression profiles in eosinophilic esophagitis
US20130052190A1 (en) 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
AU2012272858B2 (en) 2011-06-21 2017-03-09 Children's Hospital Medical Center Diagnostic methods for eosinophilic esophagitis
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CN103974706A (zh) 2011-10-06 2014-08-06 N·V·努特里奇亚 嗜酸细胞性食管炎的治疗
CA2859284A1 (en) 2011-12-16 2013-06-20 Atopix Therapeutics Limited Combination of a crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
JP2015506950A (ja) 2012-01-31 2015-03-05 ジェネンテック， インコーポレイテッド 抗ｉｇ−ｅｍ１’抗体およびそれを用いる方法
WO2013155010A1 (en) 2012-04-09 2013-10-17 Children's Hospital Medical Center Non-invasive biomarkers for eosinophilic esophagitis
HUE039387T2 (hu) * 2012-09-07 2018-12-28 Regeneron Pharma Atópiás dermatitisz kezelési módszerei egy IL-4R antagonista adagolásával
US10132809B2 (en) 2012-10-10 2018-11-20 Rhote Island Hospital Differential expression of protein markers for the diagnosis and treatment of eosinophilic esophagitis
JP2016507523A (ja) 2013-02-05 2016-03-10 エンクマフ アーゲー ＣＤ３εおよびＢＣＭＡに対する二重特異的抗体
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
SI3010539T1 (sl) 2013-06-21 2019-11-29 Regeneron Pharma Postopki za zdravljenje nazalne polipoze z administriranjem antagonista IL-4R
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
RU2552929C1 (ru) 2013-11-14 2015-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
AU2015222951B2 (en) 2014-02-28 2020-06-11 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an IL-4R antagonist
WO2016077675A1 (en) 2014-11-14 2016-05-19 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
WO2017143270A1 (en) 2016-02-19 2017-08-24 Regeneron Pharmaceuticals, Inc. Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist
TWI728172B (zh) 2016-08-18 2021-05-21 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
CN109789196B (zh) 2016-09-01 2024-03-19 瑞泽恩制药公司 用于通过施用il-4r拮抗剂来预防或治疗变态反应的方法
KR20230006049A (ko) 2016-09-22 2023-01-10 리제너론 파아마슈티컬스, 인크. Il-4r 저해제 투여에 의한 중증 아토피 피부염의 치료 방법
KR20190116420A (ko) 2017-02-17 2019-10-14 프레드 헛친슨 켄서 리서치 센터 Bcma 관련 암 및 자가면역 장애의 치료를 위한 조합 요법
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
PT3515465T (pt) 2017-08-18 2024-03-04 Regeneron Pharma Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
ES2969049T3 (es) 2017-10-30 2024-05-16 Sanofi Biotechnology Antagonista de IL-4R para uso en un método para tratar o prevenir el asma
SG11202009371WA (en) 2018-05-13 2020-10-29 Regeneron Pharma Methods for treating atopic dermatitis by administering an il-4r inhibitor
CA3103151A1 (en) 2018-06-14 2019-12-19 Ajinomoto Co., Inc. Compound having affinity substance to antibody and bioorthogonal functional group, or salt thereof
CN121102493A (zh) 2019-03-21 2025-12-12 瑞泽恩制药公司 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合
MX2021013427A (es) 2019-05-01 2022-01-31 Sanofi Biotechnology Metodos para tratar o prevenir el asma mediante la administracion un antagonista de il-33.
SG11202113312VA (en) 2019-08-05 2021-12-30 Regeneron Pharma Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
EP4010373A1 (en) 2019-08-05 2022-06-15 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
MX2022006992A (es) 2019-12-09 2022-07-13 Sanofi Biotechnology Metodos para tratar los trastornos relacionados con il-4/il-13 identificados digitalmente.
KR20220158821A (ko) 2020-03-27 2022-12-01 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
JP2023527775A (ja) 2020-05-22 2023-06-30 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ－４ｒ阻害剤の投与により好酸球性食道炎を処置する方法
CA3194111A1 (en) 2020-10-05 2022-04-14 Christine XU Methods for treating asthma in pediatric subjects by administering an il-4r antagonist
MX2023007945A (es) 2021-01-08 2023-09-21 Regeneron Pharma Metodos para tratar la alergia al cacahuate y mejorar la inmunoterapia especifica de alergeno del cacahuate mediante la administracion de un antagonista de il-4r.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015527364A (ja) 2012-08-21 2015-09-17 サノフイ Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ＩＭＭＵＮＯＬＯＧＹ ＡＮＤ ＡＬＬＥＲＧＹ ＣＬＩＮＩＣＳ ＯＦ ＮＯＲＴＨ ＡＭＥＲＩＣＡ，２０００，Ｖｏｌ．２０，Ｎｏ．２，ｐｐ．４０１－４２３
Ｊ Ａｍ Ａｃａｄ Ｄｅｒｍａｔｏｌ，２０１６，Ｖｏｌ．７４，ｐｐ．４９１－４９８
ＫＥＧＧ ＤＲＵＧ：Ｄ１０３５４ Ｄｕｐｉｌｕｍａｂ，２０１５年９月２９日，〔検索日：２０２４年４月２２日〕，＜ＵＲＬ：ｈｔｔｐｓ：／／ｗｅｂ．ａｒｃｈｉｖｅ．ｏｒｇ／ｗｅｂ／２０１５０９２９１２１０１２／ｈｔｔｐ：／／ｗｗｗ．ｇｅｎｏｍｅ．ｊｐ／ｄｂｇｅｔ－ｂｉｎ／ｗｗｗ＿ｂｇｅｔ？ｄｒ：Ｄ１０３５４＞
Ｌａｎｃｅｔ，２０１６，Ｖｏｌ．３８７，ｐｐ．４０－５２
アレルギー性鼻炎の話～原因とメカニズム～，２０１６年７月４日，〔検索日：２０２４年４月２２日〕，＜ＵＲＬ：ｈｔｔｐｓ：／／ｗｅｂ．ａｒｃｈｉｖｅ．ｏｒｇ／ｗｅｂ／２０１６０７０４１２４２１１／ｈｔｔｐｓ：／／ｗｗｗ．ｓｓｐ．ｃｏ．ｊｐ／ａｌｅｓｉｏｎ／ｒｈｉｎｉｔｉｓ／＞
医学検査，２０１５，Ｖｏｌ．６４，Ｎｏ．６，ｐｐ．７２７－７３６

Also Published As

Publication number Publication date
KR102462039B1 (ko) 2022-11-02
KR20190042702A (ko) 2019-04-24
PT3506931T (pt) 2024-08-21
MX2023004306A (es) 2023-05-04
JP2019531273A (ja) 2019-10-31
EP3506931B1 (en) 2024-07-31
EP3506931A1 (en) 2019-07-10
IL265104B2 (en) 2025-09-01
PL3506931T3 (pl) 2024-10-14
US11771743B2 (en) 2023-10-03
US20240082353A1 (en) 2024-03-14
KR20240065318A (ko) 2024-05-14
CN109789196B (zh) 2024-03-19
IL265104A (enExample) 2019-04-30
MA46098B1 (fr) 2024-11-29
CN109789196A (zh) 2019-05-21
WO2018045130A1 (en) 2018-03-08
JP2022169718A (ja) 2022-11-09
JP2024164098A (ja) 2024-11-26
IL320424A (en) 2025-06-01
HUE067888T2 (hu) 2024-11-28
IL265104B1 (en) 2025-05-01
KR102872485B1 (ko) 2025-10-20
CA3035202A1 (en) 2018-03-08
US20190183973A1 (en) 2019-06-20
ES2994774T3 (en) 2025-01-31
CN118141914A (zh) 2024-06-07
KR20220151021A (ko) 2022-11-11
JP7542582B2 (ja) 2024-08-30
EP4442323A2 (en) 2024-10-09
MA46098A (fr) 2019-07-10
EP4442323A3 (en) 2025-01-01
MX2019002344A (es) 2019-09-06

Similar Documents

Publication Publication Date Title
JP7542582B2 (ja) Ｉｌ－４ｒアンタゴニストを投与することによりアレルギーを予防又は処置するための方法
JP7575526B2 (ja) Ｉｌ－４ｒ阻害剤の投与によるアレルギー処置方法およびアレルゲン特異的免疫療法の向上方法
JP2022543815A (ja) Ｉｌ－４ｒアンタゴニストを投与することによりアレルギーを治療しアレルゲン特異的免疫療法を増強するための方法
KR20240135618A (ko) Il-4/il-13 길항제를 투여하여 아토피 행진을 약화시키는 방법
AU2017321682B2 (en) Methods for preventing or treating allergy by administering an IL-4R antagonist
HK40111341A (en) Methods for preventing or treating allergy by administering an il-4r antagonist
RU2777328C2 (ru) Способы предупреждения или лечения аллергии посредством введения антагониста il-4r
HK40009524B (en) Methods for preventing or treating allergy by administering an il-4r antagonist
HK40009524A (en) Methods for preventing or treating allergy by administering an il-4r antagonist

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200817

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210824

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220826

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220905

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220905

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220913

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20221014

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20221018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240813

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241105

R150 Certificate of patent or registration of utility model

Ref document number: 7584218

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150